All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Vopimetostat Demonstrates Early Evidence of Efficacy in MTAP-Deleted Solid Tumors

October 23rd 2025

Vopimetostat elicited responses and was considered tolerable in patients with MTAP-deleted solid tumors, including pancreatic and lung cancers.

Porustobart Plus Tislelizumab Yields Promising Responses in Pretreated MSS mCRC

October 23rd 2025

The phase 2 trial of porustobart plus tislelizumab showed antitumor activity and manageable safety in heavily pretreated MSS metastatic colorectal cancer.

FDA Grants Priority Review to Perioperative Enfortumab Vedotin Plus Pembrolizumab in Cisplatin-Ineligible MIBC

October 23rd 2025

The FDA granted priority review to enfortumab vedotin plus pembrolizumab as perioperative therapy for cisplatin-ineligible muscle-invasive bladder cancer.

Adjuvant Cemiplimab Approval Redefines Management of High-Risk CSCC

October 23rd 2025

Adjuvant cemiplimab significantly cut recurrence risk and improved disease-free survival in high-risk CSCC, establishing a new standard of care.

Cadonilimab Plus Chemo Retains Clinically Meaningful Survival Advantage in Frontline Gastric/GEJ Adenocarcinoma

October 23rd 2025

First-line cadonilimab plus chemotherapy demonstrated long-term efficacy benefits vs chemotherapy alone in patients with advanced gastric or GEJ adenocarcinoma.

Trastuzumab Rezetecan Displays PFS Benefit Vs Pyrotinib Plus Capecitabine in Pretreated HER2+ Breast Cancer

October 23rd 2025

Trastuzumab rezetecan reduced the risk of disease progression or death by 78% vs pyrotinib plus capecitabine in pretreatedHER2+ advanced breast cancer,

Real-World Studies Reinforce Axi-Cel and Liso-Cel as Effective LBCL Treatments

October 22nd 2025

Taylor Brooks, MD, discusses ways that the availability of CAR T-cell therapies has augmented the relapsed/refractory LBCL treatment paradigm.

PRO Data Further Support SERENA-6 Regimen in HR+ Breast Cancer After Emergence of ESR1 Mutations

October 22nd 2025

Switching to camizestrant plus a CDK4/6 inhibitor delayed symptom deterioration and improved QOL in HR+ breast cancer with the emergence of ESR1 mutations.

Atezolizumab Plus Bevacizumab Shows Early TTFS Edge Over TACE in HCC

October 22nd 2025

Atezolizumab plus bevacizumab displayed preliminary signs of a TTFS benefit vs TACE in intermediate-stage HCC.

Study Links Obesity-Driven Fatty Acids To Breast Cancer, Warns Against High-Fat Diets Like Keto

October 22nd 2025

A study suggests that breast cancer patients with obesity could benefit from lipid lowering therapies and should avoid high-fat weight loss regimens.

DSMB Recommends Continuation of Phase 3 Study of Bria-IMT in Metastatic Breast Cancer

October 22nd 2025

A data safety monitoring board recommended the continuation of a study of Bria-IMT plus immune checkpoint inhibition in metastatic breast cancer.

Arlo-Cel Delivers High, Durable Responses With Manageable Safety in R/R Myeloma

October 22nd 2025

Arlo-cel achieved a high ORR and CR rate with durable responses and favorable safety in relapsed/refractory multiple myeloma.

FDA Grants Fast Track Designation to EO2463 for Follicular Lymphoma

October 22nd 2025

The FDA granted fast track to EO2463, an OncoMimics immunotherapy, for low–tumor burden follicular lymphoma in the watch-and-wait setting.

Atezolizumab Plus BCG Does Not Improve EFS Vs BCG Alone in BCG-Naive NMIBC

October 22nd 2025

Atezolizumab plus BCG did not extend EFS vs BCG alone in BCG-naive, high-risk non–muscle invasive bladder cancer.

FDA Accepts NDA for Nilotinib Biosimilar XS003 for Chronic Myeloid Leukemia

October 21st 2025

XS003 shows bioequivalence to nilotinib at half the dose with a reduced food effect for patients with CML.

CAR2219 CAR T-Cell Therapy Yields Responses and a Manageable Safety Profile in R/R LBCL

October 21st 2025

CAR2219 induced high response rates in relapsed/refractory LBCL, and the role of post-infusion maintenance therapy is worthy of further study.

Liso-Cel Data Confirm Durable Efficacy and Confer Broad Use in R/R LBCL

October 21st 2025

Taylor Brooks, MD, discusses data that supported the FDA approvals of liso-cel across LBCL treatment settings and details of the agent’s toxicity profile.

Study Reveals How Bacteria in Tumors Drive Treatment Resistance in Cancer

October 21st 2025

HLX43 Nets FDA Orphan Drug Designation in Thymic Epithelial Tumors

October 21st 2025

The FDA granted orphan drug designation to HLX43 for thymic epithelial tumors

Long-Term DeFi Data Confirm Durable Efficacy and Consistent Safety of Nirogacestat in Desmoid Tumors

October 21st 2025

Final DeFi trial results show sustained responses, improved PROs, and a stable safety profile with long-term nirogacestat in desmoid tumors.